Anavex Life Sciences Corp (AVXL)

[seventhwave]

OFP, Many thanks for asking the cogent, well researched questions that are much needed on this board. Mylcroft and you are doing us retail investors a favor.
A few questions:
1. What are your thoughts on the strong 6 responders?
2. Do any Alz drug trials see such cohorts sustain outperformance (into 57 weeks) beyond initial phases of testing that may be placebo effect related?
3. Have any Alz drug trials exhibited an upturn in MMSE or ADCS-ADL for the entire study group, not just for a cohort.
4. While MMSE is the most reliable measure acknowledged by peers, is it fair to say it FULLY/COMPREHENSIVELY captures and reflects changes & progression and therefore qualitative reporting of benefits is redundant and shouldn't be considered by the FDA?
5. Are your statements setting expectations, implicitly assuming the entire study group was optimally dosed to full strength? We know Anavex has dropped their claims of synergy with DPZ and that DPZ may be a hindrance, not to mention sup-optimal dosages of 2-73 among patients.
Are you a prospective investor - just curious as to where you are coming from.
I'd love to see the conversation continue and read feedback from others like blu_1, neiu, etc.- even Peter Karol who loves charts.